ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer
Published online: 9 April 2025 - ESMO Open
Conroy T & Ducreux M, on behalf of the ESMO Guidelines Committee
- This ESMO Clinical Practice Guideline update addresses developments in the management of metastatic pancreatic cancer.
- It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen).
- Updated first- and second-line treatment recommendations are provided.
- An updated management algorithm for metastatic pancreatic cancer is also included.